Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis-Reference-Cited by-同舟云学术

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

Published:2019-01-15 Issue:2 Volume:321 Page:175
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Brown J. William L.¹²³,Coles Alasdair¹,Horakova Dana⁴⁵,Havrdova Eva⁴⁵,Izquierdo Guillermo⁶,Prat Alexandre⁷⁸,Girard Marc⁷⁸,Duquette Pierre⁷⁸,Trojano Maria⁹,Lugaresi Alessandra¹⁰,Bergamaschi Roberto¹¹,Grammond Pierre¹²,Alroughani Raed¹³,Hupperts Raymond¹⁴,McCombe Pamela¹⁵,Van Pesch Vincent¹⁶,Sola Patrizia¹⁷,Ferraro Diana¹⁷,Grand'Maison Francois¹⁸,Terzi Murat¹⁹,Lechner-Scott Jeannette²⁰²¹,Flechter Schlomo²²,Slee Mark²³,Shaygannejad Vahid²⁴,Pucci Eugenio²⁵,Granella Franco²⁶,Jokubaitis Vilija²⁷²⁸,Willis Mark²⁹,Rice Claire³⁰,Scolding Neil³⁰,Wilkins Alastair³⁰,Pearson Owen R³¹,Ziemssen Tjalf³²,Hutchinson Michael³³,Harding Katharine³⁴,Jones Joanne¹,McGuigan Christopher³³,Butzkueven Helmut²⁷²⁸³⁵,Kalincik Tomas³²⁷²⁸,Robertson Neil³⁴,

Affiliation:

1. Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom

2. NMR Research Unit, Queen Square Multiple Sclerosis Centre, University College London, Institute of Neurology, London, United Kingdom

3. Clinical Outcomes Research Unit, Melbourne Brain Centre, University of Melbourne, Melbourne, Australia

4. Department of Neurology and Center of Clinical Neuroscience, General University Hospital, Prague, Czech Republic

5. Charles University in Prague, Katerinska, Czech Republic

6. Hospital Universitario Virgen Macarena, Sevilla, Spain

7. Hopital Notre Dame, Montreal, Canada

8. CHUM and Universite de Montreal, Montreal, Canada

9. Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy

10. Department of Biomedical and Neuromotor Sciences, University of Bologna and IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

11. IRCCS Mondino Foundation, Pavia, Italy

12. CISSS Chaudi’re-Appalache, Centre-Hospitalier, Levis, Canada

13. Amiri Hospital, Qurtoba, Kuwait City, Kuwait

14. Zuyderland Medical Center, Sittard-Geleen, the Netherlands

15. University of Queensland, Brisbane, Australia; Royal Brisbane and Women's Hospital

16. Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium

17. Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy

18. Neuro Rive-Sud, Greenfield Park, Quebec, Canada

19. Medical Faculty, Ondokuz Mayis University, Kurupelit, Turkey

20. School of Medicine and Public Health, University Newcastle, Australia

21. Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, Australia

22. Asaf Harofen Medical Center, Beer-Yaakov, Zerifin, Israel

23. Flinders University, Adelaide, Australia

24. Isfahan University of Medical Sciences, Isfahan, Iran

25. UOC Neurologia, Azienda Sanitaria Unica Regionale Marche, Macerata, Italy

26. University of Parma, Parma, Italy

27. Department of Medicine, University of Melbourne, Melbourne, Australia

28. Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia

29. Department of Neurology, Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, Cardiff, United Kingdom

30. Department of Neurology, Southmead Hospital, and Clinical Neurosciences, University of Bristol, Bristol, United Kingdom

31. Abertawe Bro, Morgannwg University Local Health Board, Swansea, United Kingdom

32. Center of Clinical Neuroscience, Department of Neurology, MS Center Dresden, Dresden, Germany

33. School of Medicine and Medical Sciences, University College Dublin, St Vincent’s University, Hospital, Dublin, Ireland

34. Institute for Psychological Medicine and Clinical Neurosciences, Cardiff University, Wales

35. Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2720726/jama_brown_2019_oi_180152.pdf

Reference38 articles.

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.;The IFNB Multiple Sclerosis Study Group;Neurology,1993

2. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging—measured disease activity and burden in patients with relapsing multiple sclerosis.;Comi;Ann Neurol,2001

3. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.;Polman;N Engl J Med,2006

4. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.;Cohen;N Engl J Med,2010

5. Alemtuzumab vs interferon beta-1a in early multiple sclerosis.;Coles;N Engl J Med,2008

Cited by 328 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines;Multiple Sclerosis and Related Disorders;2024-03

2. Characterization of pathological stages in a mouse model of progressive multiple sclerosis;Neuroscience Research;2024-02

3. Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis;Neurologic Clinics;2024-02

4. Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation;Autoimmunity Reviews;2024-02

5. Evaluation of the quality and the productivity of neuroradiological reading of multiple sclerosis follow-up MRI scans using an intelligent automation software;Neuroradiology;2024-01-24